EGFR and non-small cell lung carcinoma: The BRAIN trial compared icotinib upfront with WBRT on progression to the combination of WBRT and chemotherapy in patients with EGFR-mutant NSCLC and found that patients receiving icotinib upfront with WBRT on progression had better intracranial PFS but no difference in OS [58].